Tech Company Financing Transactions
Seragon Pharmaceuticals Funding Round
Seragon Pharmaceuticals closed a $30 million Series A funding round on 10/18/2013. Backers included Aisling Capital, OrbiMed and The Column Group.
Transaction Overview
Company Name
Announced On
10/18/2013
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Proceeds Purpose
This financing provides Seragon with the resources to advance our pipeline, including ARN-810 which is currently being evaluated in a Phase I trial for ER+ metastatic breast cancer.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12780 El Camino Real 302
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Seragon Pharmaceuticals is developing small-molecule drugs for the treatment of estrogen receptor dependent breast cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Heyman
Chief Financial Officer
Patricia Millican
Vice President
Nicholas Smith
Browse more venture capital transactions:
Prev: 10/18/2013: Usermind venture capital transaction
Next: 10/18/2013: Moj.io venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs